Quoin Pharmaceuticals initiates a clinical trial in New Zealand for QRX003 lotion in pediatric PSS patients.

Quoin Pharmaceuticals begins a clinical study in New Zealand to evaluate its topical lotion, QRX003, for pediatric patients with Peeling Skin Syndrome (PSS). The lotion targets skin inflammation and barrier disruption, offering a potential treatment for a rare genetic disease with no approved cures. Quoin's strategy involves expanding clinical testing for QRX003 in various rare and orphan disease indications.

August 06, 2024
3 Articles